Ticker: XENE

Xenon Pharmaceuticals

Biotech Healthcare Biotechnology

Price 58.80

Reco Sell Potential 40 Risk 70 Updated 2026-09-09

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Xenon Pharmaceuticals is a biotechnology company focused on developing innovative therapies for neurological disorders. Its core products include treatments for conditions such as epilepsy and pain management. The company primarily generates revenue through the development and commercialization of its drug candidates, which are in various stages of clinical trials. Xenon aims to address unmet medical needs in the healthcare sector, leveraging its proprietary drug discovery platform.

Investment Profile

The investment profile of Xenon Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and potential for future revenue generation. The lack of dividends and the current negative earnings per share suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.

Category: Biotech Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Small Cap

Fundamental metrics (experimental) Updated: 2026-09-07

EPS (TTM) — earnings per share for the last 12 months, $: -4.74
EPS surprise: 2.6%
20d volatility: 2.0%

AI recommendation changes

Date	Before	After	Reason
2026-08-29	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-08-27	Sell	Hold	Strong momentum, but negative EPS raises concerns.
2026-08-21	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-08-13	Sell	Hold	Strong momentum but negative fundamentals raise concerns.
2026-08-02	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-07-18	Buy	Hold	Strong momentum but negative earnings raise concerns.
2026-07-10	Hold	Buy	Strong momentum and positive price performance indicate growth potential.
2026-06-23	Sell	Hold	Weak fundamentals with mixed momentum signals.
2026-06-03	Hold	Sell	Weak fundamentals and negative momentum raise significant risk.
2026-05-20	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-05-08	—	Sell	Weak fundamentals and negative momentum raise uncertainty.
2026-05-08	Hold	Hold	Компания показывает сильный рост за последние 60 и 120 дней, но недавние колебания цен и отрицательный EPS указывают на неопределенность в краткосрочной перспективе.
2026-03-10	—	Hold	Компания демонстрирует значительный рост цен за последние месяцы, что указывает на сильный интерес инвесторов. Однако отсутствие данных по EPS и выручке может свидетельствовать о высоком риске.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-10	H.C. Wainwright	Update	— → 74	63.36
2026-08-07	RBC Capital	Target Lowered	82 → 81	63.55
2026-05-10	Wells Fargo	Target Raised	68 → 69	56.44
2026-05-08	Needham	Target Lowered	80 → 78	56.545
2026-03-10	Deutsche Bank	Target Raised	56 → 90	60.61
2026-03-09	RBC Capital	Target Raised	59 → 80	62.76
2026-03-09	Jefferies	Target Raised	— → 100	62.76
2026-03-09	Guggenheim	Target Raised	— → 90	62.76
2026-03-09	Morgan Stanley	Target Raised	— → 97	62.76
2026-03-09	Robert W. Baird	Target Raised	— → 97	62.76
2026-03-09	Stifel Nicolaus	Target Raised	— → 89	61.58
2026-03-09	Jefferies	Update	— → 65	61.56

News Page 1 of 1

Nothing yet